Prevalence and Antimicrobial Susceptibility Pattern of Citrobacter Species with Special Reference to ESBL Production, Isolated from Different Samples from a Tertiary Care Hospital in Bihar
Authors/Creators
- 1. Tutor, Department of Microbiology, NMCH Patna, Bihar, India
- 2. SMO and Infection Control Officer, Department of Central Pathology, BMIMSH Pawapuri, Bihar, India
- 3. Professor and Head, Department of Microbiology, NMCH Patna, Bihar, India
- 4. Assistant Professor, Department of Biochemistry, NMCH Patna, Bihar, India
Description
Introduction: Citrobacter species is gram negative, enteric bacilli that colonize in moist environment and found mostly in water, soil, food, and the intestines of animals and humans. They cause a wide spectrum of infections involving the urinary tract, liver, biliary tract, peritoneum, intestines, one, respiratory tract, endocardium, wounds, soft tissue, meninges, and the bloodstream. Increasing resistance to beta-lactam drugs especially the 3rd-generation cephalosporin in Citrobacter species is predominantly due to the production of multidrug resistant enzymes in particular extended spectrum beta-lactamases (ESBLs). Material & Method: This was a hospital lab based observational study carried out from the 500 samples, – 100 from each sample type (100 Urine, 100 Pus, 100 Sputum, 100 Blood and 100 Body fluid) collected over a period of 6 months from 13-08-2022 to 23-02-2023 at NMCH, Patna Bihar. Among these processed samples positive isolates of Citrobacter species are recovered and for further study sent to the department of Microbiology. First find out Antimicrobial susceptibility pattern and ESBL producing strain from isolated Citrobacter species then find out total prevalence and ESBL, non-ESBL prevalance. Antimicrobial susceptibility pattern tested against different antibiotics and determine the antibiogram of these isolates. ESBL production in all these isolates are detected by using double disc synergy test (DDST). Result: Out of 500 samples, 44 (8.80%) were detected positive for Citrobacter species isolates. Out of these 44 clinical isolates of Citrobacter species recruited for this study, 26 isolates (i.e. 59%) were confirmed to be ESBL producers by the DDST method and rest 18 (41%) non-ESBL producer. AST pattern shows high resistance rate to Cefotaxime, Cotrimoxazole, Ciprofloxacin, Gentamycin and more sensitive to Imipenem and with Colistin no resistant found in this study. Conclusion: From our results, it could be deduced that 59% of Citrobacter isolates harbour or express ESBLs; and they are resistant to commonly used antibiotics inclusive of some beta-lactams and non-beta-lactam antibiotics. There is therefore need for proper AST monitoring and detection of resistant antibiotics from clinically important bacterial pathogens so as to guide therapy and to contain their nefarious effect.
Abstract (English)
Introduction: Citrobacter species is gram negative, enteric bacilli that colonize in moist environment and found mostly in water, soil, food, and the intestines of animals and humans. They cause a wide spectrum of infections involving the urinary tract, liver, biliary tract, peritoneum, intestines, one, respiratory tract, endocardium, wounds, soft tissue, meninges, and the bloodstream. Increasing resistance to beta-lactam drugs especially the 3rd-generation cephalosporin in Citrobacter species is predominantly due to the production of multidrug resistant enzymes in particular extended spectrum beta-lactamases (ESBLs). Material & Method: This was a hospital lab based observational study carried out from the 500 samples, – 100 from each sample type (100 Urine, 100 Pus, 100 Sputum, 100 Blood and 100 Body fluid) collected over a period of 6 months from 13-08-2022 to 23-02-2023 at NMCH, Patna Bihar. Among these processed samples positive isolates of Citrobacter species are recovered and for further study sent to the department of Microbiology. First find out Antimicrobial susceptibility pattern and ESBL producing strain from isolated Citrobacter species then find out total prevalence and ESBL, non-ESBL prevalance. Antimicrobial susceptibility pattern tested against different antibiotics and determine the antibiogram of these isolates. ESBL production in all these isolates are detected by using double disc synergy test (DDST). Result: Out of 500 samples, 44 (8.80%) were detected positive for Citrobacter species isolates. Out of these 44 clinical isolates of Citrobacter species recruited for this study, 26 isolates (i.e. 59%) were confirmed to be ESBL producers by the DDST method and rest 18 (41%) non-ESBL producer. AST pattern shows high resistance rate to Cefotaxime, Cotrimoxazole, Ciprofloxacin, Gentamycin and more sensitive to Imipenem and with Colistin no resistant found in this study. Conclusion: From our results, it could be deduced that 59% of Citrobacter isolates harbour or express ESBLs; and they are resistant to commonly used antibiotics inclusive of some beta-lactams and non-beta-lactam antibiotics. There is therefore need for proper AST monitoring and detection of resistant antibiotics from clinically important bacterial pathogens so as to guide therapy and to contain their nefarious effect.
Files
IJPCR,Vol16,Issue9,Article22.pdf
Files
(664.8 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:2dae029f257d0c0343e32e35f000527d
|
664.8 kB | Preview Download |
Additional details
Dates
- Accepted
-
2024-08-26
Software
- Repository URL
- https://impactfactor.org/PDF/IJPCR/16/IJPCR,Vol16,Issue9,Article22.pdf
- Development Status
- Active
References
- 1. Anderson MT, Mitchell LA, Zhao L, Mobley HLT. Citrobacter freundii fitness during bloodstream infection. Sci Rep. 2018 Aug 7; 8(1):11792. doi: 10.1038/s41598-018-30196-0. 2. Lipsky BA, Hook 3rd EW, Smith AA, Plorde JJ. Citrobacter infections in humans: experience at the Seattle Veterans Administration Medical Center and a review of the literature. Rev Infect Dis 1980; 2(5):746e60. 3. Pepperell C, Kus JV, Gardam MA, Humar A, Burrows LL. Lowvirulence Citrobacter species encode resistance to multiple antimicrobials. Antimicrob Agents Chemother 2002; 46(11):3555e60. 4. Kumar P, Ghosh S, Rath D, Gadpayle AK. Multidrug resistant Citrobacter: an unusual cause of liver abscess. BMJ Case Rep 2013:2013.http://dx.doi.org/10.1136/bcr-2013- 008714.bcr2013008714. 5. Jones RN, Jenkins SG, Hoban DJ, Pfaller MA, Ramphal R. In vitro efficacy of six cephalosporins tested against Enterobacteriaceae isolated at 38 North American medical centres participating in the SENTRY Antimicrobial Surveillance Program, 1997e1998. Int J Antimicrob Agents 2000; 15(2):111e8. 6. Lavigne JP, Defez C, Bouziges N, Mahamat A, Sotto A. Clinical and molecular epidemiology of multidrug-resistant Citrobacter spp. infections in a French university hospital. Eur J Clin Microbiol Infect Dis 2007; 26(6):439e41. 7. Lin FC, Devoe WF, Morrison C, Libonati J, Powers P, Gross RJ, et al. Outbreak of neonatal Citrobacter diversus meningitis in a suburban hospital. Pediatr Infect Dis J 1987; 6(1):50e5. 8. Lin FC, Devoe WF, Morrison C, Libonati J, Powers P, Gross RJ, et al. Outbreak of neonatal Citrobacter diversus meningitis in a suburban hospital. Pediatr Infect Dis J 1987; 6(1):50e5. 9. El Harrif-Heraud Z, Arpin C, Benliman S, Quentin C. Molecular epidemiology of a nosocomial outbreak due to SHV-4-producing strains of Citrobacter diversus. J Clin Microbiol 1997; 35(10):2561e7. 10. Mohanty S, Singhal R, Sood S, Dhawan B, Kapil A, Das BK. Citrobacter infections in a tertiary care hospital in Northern India. J Infect 2007; 54(1):58e64. 11. Gupta N, Yadav A, Choudhary U, Arora DR. Citrobacter bacteremia in a tertiary care hospital. Scand J Infect Dis 2003; 35(10):765e8. 12. Samonis G, Anaissie E, Elting L, Bodey GP. Review of Citrobacter bacteremia in cancer patients over a sixteen-year period. Eur J Clin Microbiol Infect Dis 1991; 10(6):479e85. 13. Hanson ND, Sanders CC. Regulation of inducible AmpC betalactamase expression among Enterobacteriaceae. Curr Pharm Des 1999; 5(11):881e94.14. Deal EN, Micek ST, Ritchie DJ, Reichley RM, Dunne Jr WM, Kollef MH. Predictors of inhospital mortality for bloodstream infections caused by Enterobacter species or Citrobacter freundii. Pharmacotherapy 2007; 27(2):191e9. 15. Cox CE. Nosocomial urinary tract infections. Urol 1988; 32:210-5. 16. Metri BC, Jyothi P, Peerapur BV. Antibiotic resistance in Citrobacter spp. isolated from urinary tract infection. Urol Ann 2013; 5:312- 3. 17. Pammi M, Zhong D, Johnson Y, Revell P, Versalovic J. Polymicrobial bloodstream infections in the neonatal intensive care unit are associated with increased mortality: a casecontrol study. BMC Infect Dis 2014; 14:390. 18. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. 32nd ed. CLSI supplement M100S. Wayne, Pennsylvania USA, 2022. 19. Nayar R, Shukla I, Sultan A. Epidemiology, prevalence and identification of Citrobacter species in clinical specimens in a tertiary care hospital in India. International Journal of Scientific and Research Publications. 2014 Apr; 4(4):1-6. 20. Poonam AR, Bilolikar AK, Reddy SG. Prevalence and antimicrobial susceptibility pattern of Citrobacter species in various clinical samples in a tertiary care hospital. J Med Sci Res. 2019; 7(4):103-108. DOI: http://dx.doi.org/10. 17727/JMSR.2019/7-18 21. John MS, Munilakshmi P, Deepa T. Significance of Citrobacter as an emerging nosocomial pathogen with special reference to its antibiotic susceptibility pattern in a tertiary care hospital, Nellore, AP. India. Int J Curr Microbiol App Sci.2015; 4(7):841–847. 22. Mary Dhason et al Prevalence Of Citrobacter Species In Various Clinical Samples And Their Antibiotic Susceptibility Pattern-A Study From A Tertiary Care Center In South India International Journal of Academic Medicine and Pharmacy (www.academicmed.org) ISSN (O): 2687-5365; ISSN (P): 2753-6556.